TY  - JOUR
A1  - Kittel-Schneider, Sarah
A1  - Felice, Ethel
A1  - Buhagiar, Rachel
A1  - Lambregtse-van den Berg, Mijke
A1  - Wilson, Claire A.
A1  - Banjac Baljak, Visnja
A1  - Vujovic, Katarina Savic
A1  - Medic, Branislava
A1  - Opankovic, Ana
A1  - Fonseca, Ana
A1  - Lupattelli, Angela
T1  - Treatment of peripartum depression with antidepressants and other psychotropic medications: a synthesis of clinical practice guidelines in Europe
JF  - International Journal of Environmental Research and Public Health
N2  - This study examined (1) the availability and content of national CPGs for treatment of peripartum depression, including comorbid anxiety, with antidepressants and other psychotropics across Europe and (2) antidepressant and other psychotropic utilization data as an indicator of prescribers' compliance to the guidelines. We conducted a search using Medline and the Guidelines International Network database, combined with direct e-mail contact with national Riseup-PPD COST ACTION members and researchers within psychiatry. Of the 48 European countries examined, we screened 41 records and included 14 of them for full-text evaluation. After exclusion of ineligible and duplicate records, we included 12 CPGs. Multiple CPGs recommend antidepressant initiation or continuation based on maternal disease severity, non-response to first-line non-pharmacological interventions, and after risk-benefit assessment. Advice on treatment of comorbid anxiety is largely missing or unspecific. Antidepressant dispensing data suggest general prescribers' compliance with the preferred substances of the CPG, although country-specific differences were noted. To conclude, there is an urgent need for harmonized, up-to-date CPGs for pharmacological management of peripartum depression and comorbid anxiety in Europe. The recommendations need to be informed by the latest available evidence so that healthcare providers and women can make informed, evidence-based decisions about treatment choices.
KW  - clinical practice guideline
KW  - depression
KW  - anxiety
KW  - antidepressant
KW  - psychotropic medications
KW  - peripartum
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-262130
SN  - 1660-4601
VL  - 19
IS  - 4
ER  - 
TY  - JOUR
A1  - Kittel-Schneider, Sarah
A1  - Kenis, Gunter
A1  - Schek, Julia
A1  - van den Hove, Daniel
A1  - Prickaerts, Jos
A1  - Lesch, Klaus-Peter
A1  - Steinbusch, Harry
A1  - Reif, Andreas
T1  - Expression of monoamine transporters, nitric oxide synthase 3, and neurotrophin genes in antidepressant-stimulated astrocytes
JF  - Frontiers in Psychiatry
N2  - Background: There is increasing evidence that glial cells play a role in the pathomechanisms of mood disorders and the mode of action of antidepressant drugs. 
Methods: To examine whether there is a direct effect on the expression of different genes encoding proteins that have been implicated in the pathophysiology of affective disorders, primary astrocyte cell cultures from rats were treated with two different antidepressant drugs, imipramine and escitalopram, and the RNA expression of brain-derived neurotrophic factor (Bdnf), serotonin transporter (5Htt), dopamine transporter (Dat), and endothelial nitric oxide synthase (Nos3) was examined. 
Results: Stimulation of astroglial cell culture with imipramine, a tricyclic antidepressant, led to a significant increase of the Bdnf RNA level whereas treatment with escitalopram did not. In contrast, 5Htt was not differentially expressed after antidepressant treatment. Finally, neither Dat nor Nos3 RNA expression was detected in cultured astrocytes. 
Conclusion: These data provide further evidence for a role of astroglial cells in the molecular mechanisms of action of antidepressants.
KW  - monoamine transporters
KW  - BDNF
KW  - geneexpression
KW  - astrocytes
KW  - glia
KW  - depression
KW  - antidepressant
KW  - mechanismofaction
KW  - nitricoxidesynthase
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-123627
VL  - 3
ER  -